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Chemicals found in the environment have been found to behave like the body's natural estrogen, 
estradiol. These exogenous estrogen-mimicking compounds have been termed xenoestrogens. Both 
estradiol and xenoestrogens can bind two estrogen receptors (ERs), ER alpha and ER beta, to elicit 
biological responses. The receptors are ligand inducible transcription factors that exhibit unique biological 
actions. While estradiol binds both receptors equally, some xenoestrogens have been shown to bind ER 
beta preferentially. When the ER is bound, the ligand induces a unique ER shape and in turn causes an 
array of tissue-specific biological responses. For example, the ligand tamoxifen, a commonly used breast 
cancer pharmaceutical, exhibits an ER antagonist response in the breast and an ER agonist response in 
the bone. This dual ligand quality characterizes what is now known as a selective estrogen receptor 
modulator (SERM). Peptide profiling, a novel ER ligand screening assay, is a method that can potentially 
identify SERMS by correlating in vitro ER conformation with in vivo biological response. Each ligand is 
screened using a two-hybrid fusion protein reporter gene assay. Upon ligand binding, the ER assumes a 
conformation; with this induced shape, some ER-interacting peptides will be able to bind while others will 
not. After screening a ligand against a library of fifteen different peptides, a unique peptide profile will 
figuratively illustrate the induced ER conformation. Eight xenoestrogens were screened in this 
experiment: estradiol, a natural physiological estrogen; resveratrol and genistein, two phytoestrogens; 
MPP, bisphenol A, and 4-hydroxytamoxifen, all synthetic estrogens; α-endosulfan and methoxychlor, both 
insecticides used on crops. Each ligand was found to have a unique peptide profile and, implicitly, a 
distinct ER conformation. The next step will be to determine each ligand’s tissue specific activity and 
identify the unique peptide fingerprint that predicts its in vivo biological response. By correlating a ligand’s 
tissue specific estrogenic activity with its unique ER conformation, peptide profiling will not only further 
elucidate tissue-specific ER activity differences but could also be used as a high-throughput screening 
tool for other potential environmental xenoestrogens and identify novel therapeutic SERMs. 
